Tisento Therapeutics
Founded 2023 · $81.0M raised
- Employees
- 11–50
- Founded
- 2023
- Business Model
- B2B
- Website
- tisentotx.com
- Total Funding
- $81.0M
- Last Round
- $81.0M Series AAug 2023
- Rounds
- 1
About
Tisento Therapeutics is a clinical-stage biotech developing treatments for rare genetic mitochondrial diseases, including MELAS, with lead candidate zagociguat.
Summary
Tisento Therapeutics is a Biotech company, founded in 2023. It has raised $81.0M in total across 1 round, most recently a $81.0M Series A round in Aug 2023. Investors include Polaris Partners, Sanofi Ventures and J. Wood Capital Advisors.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2023
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...